UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~December~~April 234, ~~2024~~2025

CHINA PHARMA HOLDINGS, INC.

(Exact name of Registrant as specified in charter)

Nevada	001-34471	73-1564807
(State or other jurisdiction	(Commission File No.)	(IRS Employer
of Incorporation)		Identification No.)

Second Floor, No. 17, Jinpan Road

Second Floor, No. 17, Jinpan Road

Haikou, Hainan Province, China

570216

(Address of principal executive offices)

(Zip Code)

Haikou, Hainan Province, China 570216

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: +86 898-6681-1730 (China)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)

☐

Soliciting material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		CPHI		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 17.~~02.~~01 ~~Termination~~Regulation ofFD ~~a Material Definitive Agreement.~~Disclosure

On April ~~December 23~~4, ~~2024~~2025, China Pharma Holdings, Inc., (the “Company”) ~~and~~issued ~~that~~a ~~certain~~press ~~investor~~release, ~~(the~~included ~~“Investor”)~~herewith ~~reached~~as anExhibit ~~agreement~~99.1, toannouncing that ~~rescind~~it ~~(the~~expects ~~“Recission”) that~~to ~~certain~~implement ~~securities~~a 1-for-10 reverse ~~purchase~~stock ~~agreement~~split ~~(the~~effective ~~“Agreement”)~~Tuesday, ~~dated~~April ~~December~~15, 122025, ~~2024.~~that ~~The~~every ~~material~~10 ~~terms~~shares of ~~such~~the ~~Agreement~~pre-split ~~were~~common ~~disclosed~~stock inof the ~~current~~Company, ~~report~~par onvalue ~~Form~~$0.001 ~~8-K~~per ~~filed~~share, bywill ~~the~~be ~~Company~~converted ~~with~~into ~~the~~one ~~Securities~~post-split ~~and~~common ~~Exchange~~stock ~~Commission~~of onthe ~~December 13~~Company, ~~2024.~~par value As$0.001 aper ~~result~~share, ofwith ~~such~~trading ~~Recission,~~to ~~the~~begin ~~Agreement~~on isa ~~deemed~~split-adjusted ~~void~~basis ~~from~~at the ~~beginning~~market open on that day.

The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.

~~SIGNATURES~~Item 9.01 Financial Statements and Exhibits

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~(d) Exhibits.

Dated: December 26, 2024

99.1	Press Release, dated April 4, 2025.

104	Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL)

~~CHINA PHARMA HOLDINGS, INC. By: /s/ Zhilin Li Name: Zhilin Li Title: President and Chief Executive Officer~~1

2SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 4, 2025

	CHINA PHARMA HOLDINGS, INC.

	By:	/s/ Zhilin Li
	Name:	Zhilin Li
	Title:	President and Chief Executive Officer

Filing Compare · CHINA PHARMA HOLDINGS, INC.